Jesteśmy na EACR w Barcelonie

Można nas spotkać na konferencji The European Association for Cancer Research w Barcelonie (7-10 lipca), gdzie prezentujemy wyniki naszych badań:
NPM-ALK I1171T mutation confers resistance to crizotinib in anaplastic large cell lymphoma.
Differential gene transcription response to the treatment with JAK2 inhibitors – Ruxolitinib, SAR302503 and LY2784544.
Gene silencing of β-catenin inhibits growth of Wnt/β-catenin pathway dependent colon cancer cell lines.

Tweet about this on TwitterShare on LinkedInShare on FacebookShare on Google+